Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

12 ottobre 2026 aggiornato da: AbbVie

A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer

Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.

ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 6 parts where participants will receive ABBV-901, alone or in combination with other anticancer therapies. Around 285 participants will be enrolled in the study at approximately 45 sites around the world.

In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901 alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901 in combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV bevacizumab. in Part 5, participants will receive escalating doses of IV ABBV-901 in combination with IV carboplatin and IV bevacizumab and in part 6, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV carboplatin and IV bevacizumab. The total study duration will be approximately 3 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Tipo di studio

Interventistico

Iscrizione (Stimato)

285

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • New South Wales
      • Blacktown, New South Wales, Australia, 2148
        • Reclutamento
        • Blacktown Hospital /ID# 282426
    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Reclutamento
        • Monash Health - Monash Medical Centre - Clayton /ID# 281468
      • Melbourne, Victoria, Australia, 3000
        • Reclutamento
        • Peter MacCallum Cancer Centre. /ID# 281751
    • Pays de la Loire Region
      • Saint-Herblain, Pays de la Loire Region, Francia, 44805
        • Reclutamento
        • Institut De Cancerologie De L'Ouest - Site Rene Gauducheau /ID# 280684
    • Rhone
      • Lyon, Rhone, Francia, 69373
        • Reclutamento
        • Centre Leon Berard /ID# 280575
    • Chiba
      • Kashiwa-shi, Chiba, Giappone, 277-8577
        • Reclutamento
        • National Cancer Center Hospital East /ID# 278604
    • Saitama
      • Hidaka, Saitama, Giappone, 350-1298
        • Reclutamento
        • Saitama Medical University International Medical Center /ID# 278437
    • Shizuoka
      • Sunto-gun, Shizuoka, Giappone, 411-8777
        • Reclutamento
        • Shizuoka Cancer Center /ID# 278538
      • Haifa, Israele, 3109601
        • Reclutamento
        • Rambam Health Care Campus /ID# 278418
      • Jerusalem, Israele, 91120
        • Reclutamento
        • Hadassah Medical Center-Hebrew University /ID# 278420
    • Tel Aviv
      • Ramat Gan, Tel Aviv, Israele, 5265601
        • Reclutamento
        • The Chaim Sheba Medical Center /ID# 278416
      • Lisbon, Portogallo, 1649-035
        • Reclutamento
        • Unidade Local de Saude de Santa Maria /ID# 280296
      • Porto, Portogallo, 4200-072
        • Reclutamento
        • Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 280293
      • Barcelona, Spagna, 08035
        • Reclutamento
        • Hospital Universitari Vall d Hebron /ID# 280442
      • Madrid, Spagna, 28040
        • Reclutamento
        • Hospital Universitario Fundacion Jimenez Diaz /ID# 280440
      • Madrid, Spagna, 28050
        • Reclutamento
        • Hospital Universitario HM Sanchinarro /ID# 280439
    • Madrid
      • Majadahonda, Madrid, Spagna, 28222
        • Reclutamento
        • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 280459
    • California
      • Duarte, California, Stati Uniti, 91010
        • Reclutamento
        • City of Hope National Medical Center /ID# 281381
      • Irvine, California, Stati Uniti, 92618
        • Reclutamento
        • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914
    • Colorado
      • Denver, Colorado, Stati Uniti, 80218
        • Reclutamento
        • Sarah Cannon Research Institute at HealthONE /ID# 278785
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • Reclutamento
        • University of Chicago Medical Center /ID# 278295
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68198
        • Reclutamento
        • University Of Nebraska Medical Center /ID# 281020
    • Texas
      • San Antonio, Texas, Stati Uniti, 78229
        • Reclutamento
        • NEXT Oncology - San Antonio /ID# 278606
    • Utah
      • West Valley City, Utah, Stati Uniti, 84119
        • Reclutamento
        • Start Mountain Region /ID# 278609
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
        • Reclutamento
        • Next Virginia /ID# 278607
      • Taipei, Taiwan, 112
        • Reclutamento
        • Taipei Veterans General Hospital /ID# 281349
      • Taipei, Taiwan, 100
        • Reclutamento
        • National Taiwan University Hospital /ID# 280701

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization [WHO] criteria).
  • Participants enrolled in backfill (Part 1) must provide consent to paired fresh biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion.

For Parts 1-4:

- Participants must be considered platinum resistant or platinum ineligible. Platinum resistant disease is defined as radiographic progression within 6 months (up to 182 days) after the last dose of the most recent platinum therapy).

For Parts 5-6:

- Participants will have platinum-sensitive disease defined as radiographic progression > 6 months from last dose of platinum-based chemotherapy. Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.

Exclusion Criteria:

  • Ovarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, mucinous, carcinosarcoma or sarcomatous histology, mixed tumors or low grade/borderline ovarian tumor.
  • Participants with platinum refractory disease.
  • Prior therapy with an antibody-drug conjugate containing a topoisomerase inhibitor.
  • Prior history of Grade >= 2 interstitial lung disease (ILD) or pneumonitis.
  • Prior history of Grade 2 >= 2 ILD or pneumonitis or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan.

For Parts 3-6:

  • History of Grade 3/4 adverse events that, in the opinion of the investigator, are attributed to bevacizumab.
  • History of clinically significant cardiac disease including CHF Class II or higher NYHA; active coronary artery disease, MI within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted).
  • Echocardiogram with ejection fraction <= 50% and no other clinically significant cardiac abnormalities that in the opinion of the investigator, would increase the participants susceptibility to cardiac toxicity.

For Parts 5-6:

- Participants who had prior allergic reaction to platinum containing compound.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Part 1: ABBV-901 Dose Escalation

Participants will receive escalating doses of ABBV-901 alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Sperimentale: Part 2: ABBV-901 Optimization Dose A

Participants will receive ABBV-901 dose A alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Sperimentale: Part 2: ABBV-901 Optimization Dose B

Participants will receive ABBV-901 dose B alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Sperimentale: Part 2: ABBV-901 Optimization Dose C

Participants will receive ABBV-901 dose C alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Sperimentale: Part 3: ABBV-901 + Bevacizumab Escalation

Participants will receive escalating doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Sperimentale: Part 4: ABBV-901 + Bevacizumab Expansion

Participants will receive the recommended doses for expansion doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Sperimentale: Part 5: ABBV-901 + Carboplatin + Bevacizumab Escalation

Participants will receive escalating doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Intravenous (IV)

Sperimentale: Part 6: ABBV-901 + Carboplatin + Bevacizumab Expansion

Participants will receive the recommended doses for expansion doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Intravenous (IV)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Participants with Adverse Events (AE)
Lasso di tempo: Up to Approximately 3 Years

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.

Up to Approximately 3 Years
Overall Response (as assessed by the investigator)
Lasso di tempo: Up to Approximately 3 Years

Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator.

Up to Approximately 3 Years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall Response (as assessed by independent central review)
Lasso di tempo: Up to Approximately 3 Years

Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by independent central review (ICR).

Up to Approximately 3 Years
Duration of Response (DOR)
Lasso di tempo: Up to Approximately 3 Years

DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST Version 1.1 criteria to disease progression or death of any cause, whichever occurs earlier.

Up to Approximately 3 Years
Progression-free survival (PFS)
Lasso di tempo: Up to Approximately 3 Years

PFS is defined as time from first study treatment to a documented disease progression according to RECIST Version 1.1 (or other assessment criteria), as determined by the investigator, or death due to any cause, whichever occurs earlier.

Up to Approximately 3 Years
Overall Survival (OS)
Lasso di tempo: Up to Approximately 3 Years

OS is defined as time from first study treatment to death due to any cause.

Up to Approximately 3 Years
Disease Control Rate
Lasso di tempo: Up to Approximately 3 Years

Disease Control Rate is defined as the percentage of participants with best overall response (BOR) of stable disease (SD), PR or better per investigator review according to RECIST version 1.1 criteria.

Up to Approximately 3 Years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: ABBVIE INC., AbbVie

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

27 novembre 2025

Completamento primario (Stimato)

1 dicembre 2028

Completamento dello studio (Stimato)

1 gennaio 2029

Date di iscrizione allo studio

Primo inviato

2 dicembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

2 dicembre 2025

Primo Inserito (Effettivo)

12 dicembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi